Ahead of #ES­MO22: An­a­lysts poke at Gilead’s Trodelvy OS; Am­gen and Mi­rati try to out-KRAS each oth­er

Like a num­ber of oth­er con­fer­ences this year, ES­MO — ​​the Eu­ro­pean So­ci­ety for Med­ical On­col­o­gy — is re­turn­ing as an in-per­son event in Paris next week. Just last week, End­points as­so­ciate ed­i­tor Kyle LaHu­cik was in Barcelona for ESC, re­port­ing on the lat­est slate of car­di­ol­o­gy drugs.

Al­ready, com­pa­nies are gear­ing up for the Eu­ro­pean can­cer con­fer­ence, tout­ing their late-break­er ac­cep­tances and up­com­ing pre­sen­ta­tions. (Just yes­ter­day, Am­gen post­ed a Phase III win for its KRAS drug Lumakras in non-small cell lung can­cer, for which it will be pre­sent­ing da­ta on the sec­ond to last day of the con­fer­ence.) Ahead of ES­MO, here’s some back­ground on a few of the most an­tic­i­pat­ed read­outs set to come:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER